Voriconazole plus flucytosine is not superior to amphotericin B deoxycholate plus flucytosine as an induction regimen for cryptococcal meningitis treatment
Mycoses · 2024
DOI: 10.1111/myc.13674 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, 2024. Verfasst von Handan Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Flucytosine, Meningitis, Cryptococcal, Amphotericin B, Deoxycholic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: North China Pharmaceutical Company.
Abstract (Originalsprache)
Background
The efficacy and side effects of voriconazole plus 5‐flucytosine (Vori + 5‐FC) versus amphotericin B deoxycholate plus 5‐flucytosine (AmBd + 5‐FC) as an induction treatment for cryptococcal meningitis are unknown.
Methods
Forty‐seven patients treated with Vori + 5‐FC and 92 patients treated with AmBd + 5‐FC were included in the current study after propensity score matching (PSM) at a ratio of 1:2. Two‐week laboratory test results and 90‐day mortality were compared between the two groups.
Results
After 2 weeks of induction treatment, the CSF Cryptococcus sterile culture rate was 57.1% in the Vori + 5‐FC group and 76.5% in the AmBd + 5‐FC group ( p = .026). No difference was found in the normalization of CSF indicators (glucose, total protein, intracranial pressure and India ink sterile rate) between the two groups. Both the Vori + 5FC regimen and AmBd + 5‐FC regimen obviously decreased haemoglobin concentrations, platelet counts and serum potassium levels (all p ≤ .010). Notably, the Vori + 5FC regimen did not influence serum creatinine levels ( p = .263), while AmBd + 5FC increased serum creatinine levels ( p = .019) after 2‐week induction treatment. The Vori + 5‐FC group and AmBd + 5‐FC group had similar 90‐day cumulative survival rates (89.9% vs. 87.8%, p = .926).
Conclusion
The Vori + 5‐FC regimen was associated with low 2‐week CSF sterile culture and was not superior to AmBd + 5‐FC as induction therapy in terms of the 90‐day cumulative survival rate of CM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
- The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
- Chongqing Public Health Medical Center, Southwest University Public Health Hospital, Chongqing, China.
- Department of Infectious Diseases, The Ninth Hospital of Nanchang, Nanchang, China.
- Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China.
ORCID-Profile: Lijun Xu
Förderung
- North China Pharmaceutical Company
Zitieren
APA
Zhao, H., Lu, Y., Li, S., Qin, J., Xu, M., Ye, H., Yang, Z., Rao, J., Chen, G., Su, F., Hu, Z., & Xu, L. (2024). Voriconazole plus flucytosine is not superior to amphotericin B deoxycholate plus flucytosine as an induction regimen for cryptococcal meningitis treatment. Mycoses. https://doi.org/10.1111/myc.13674
Vancouver
Zhao H, Lu Y, Li S, Qin J, Xu M, Ye H, et al. Voriconazole plus flucytosine is not superior to amphotericin B deoxycholate plus flucytosine as an induction regimen for cryptococcal meningitis treatment. Mycoses. 2024. doi:10.1111/myc.13674
BibTeX
@article{Zhao2024,
author = {Zhao, Handan and Lu, Yanqiu and Li, Shan and Qin, Jiangying and Xu, Miaomiao and Ye, Hui and Yang, Zongxing and Rao, Jianfeng and Chen, Guochun and Su, Feifei and Hu, Zhiliang and Xu, Lijun},
title = {Voriconazole plus flucytosine is not superior to amphotericin B deoxycholate plus flucytosine as an induction regimen for cryptococcal meningitis treatment},
journal = {Mycoses},
year = {2024},
doi = {10.1111/myc.13674}
}
EUVIMED